Home Why Gilead Is Still A Growth Stock - Focus On HIV And China, With Projections For 2016
 

Keywords :   


Why Gilead Is Still A Growth Stock - Focus On HIV And China, With Projections For 2016

2015-12-08 14:07:47| Biotech - Topix.net

Yet it continues to demonstrate growing earnings power from medical trends in HIV, new products in HIV and HCV, and geographic expansion. At its current valuation, I believe that Gilead Sciences is reasonably valued even if its non-HCV, non-HIV pipeline flops.

Tags: for with china stock

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
28.09Weekly Recap: AkzoNobel, BASF, Axalta, PPG Top This Weeks Stories
28.09Post-Tropical Cyclone Helene Public Advisory Number 20
28.09Hurricane Isaac Graphics
28.09Hurricane Isaac Forecast Discussion Number 10
28.09Hurricane Isaac Wind Speed Probabilities Number 10
28.09Hurricane Isaac Public Advisory Number 10
28.09Summary for Hurricane Isaac (AT5/AL102024)
28.09Hurricane Isaac Forecast Advisory Number 10
More »